How should tolvaptan be administered and how should serum sodium be monitored?

How to Give Tolvaptan and Monitor Sodium

For ADPKD, start tolvaptan at 45 mg upon waking and 15 mg eight hours later, with morning blood draws before dosing to monitor serum sodium levels; for hyponatremia, initiate in-hospital at 15 mg once daily with sodium checks every 6-8 hours during the first 24-48 hours to prevent overcorrection exceeding 12 mEq/L per 24 hours. 1, 2

Administration Protocol

For ADPKD (Chronic Use)

Starting dose:

• 45 mg upon waking
• 15 mg eight hours later (split dosing) 1

Titration schedule:

• Wait at least 1 week before uptitrating
• Intermediate dose: 60 mg AM + 30 mg PM
• Target dose: 90 mg AM + 30 mg PM
• Continue until approaching kidney replacement therapy 1

Key patient counseling:

• Drink enough water to replace urinary losses (no fluid restriction)
• Skip doses during "sick days" with volume depletion risk (vomiting, diarrhea, limited water access, hot weather activities)
• Consume liquids without sugar or fat
• Adopt low-sodium diet to reduce polyuria 1

For Hyponatremia (Acute Use)

Critical requirement: Hospital initiation mandatory 2

Starting dose:

• 15 mg once daily without regard to meals 2

Titration:

• Increase to 30 mg after at least 24 hours
• Maximum 60 mg once daily as needed
• Limit total duration to 30 days maximum to minimize liver injury risk 2

Avoid fluid restriction during first 24 hours - this paradoxically increases overcorrection risk 2

Sodium Monitoring Protocol

For ADPKD

Serum sodium monitoring:

• Obtain morning blood samples before tolvaptan dose 1
• Serum sodium levels provide insight into adequacy of water intake 1
• No specific frequency mandated for sodium alone, but monthly visits required for liver function tests (see below) 1

For Hyponatremia

Intensive monitoring required:

• Check sodium every 6-8 hours during initiation and titration 2
• Monitor neurologic status closely 2
• Patients with baseline sodium <130 mEq/L are at highest risk for rapid correction 2

Target correction rates:

• Do not exceed 12 mEq/L rise in 24 hours 2
• Aim for <8 mEq/L rise in first 8 hours 2
• Slower rates advisable in high-risk patients (severe malnutrition, alcoholism, advanced liver disease) 2

If overcorrection occurs:

• Discontinue or interrupt tolvaptan immediately
• Consider hypotonic fluid administration
• Monitor for osmotic demyelination syndrome symptoms (dysarthria, mutism, dysphagia, lethargy, seizures) 2

Mandatory Liver Monitoring (ADPKD Only)

Frequency:

• Monthly for first 18 months
• Every 3 months thereafter until discontinuation 1

Obtain morning samples before tolvaptan dose 1

Hold tolvaptan if:

• AST/ALT ≥3× ULN, or
• AST/ALT >2× baseline (even if <2× ULN), or
• AST/ALT >2× ULN with symptoms (fatigue, nausea, vomiting, anorexia, right upper quadrant pain, fever, rash, jaundice, pruritus, ascites) 1

Action steps:

• Repeat liver function tests within 48-72 hours
• Assess for alternative etiologies
• Permanently discontinue if ≥3× ULN persists unless alternative explanation found 1

Critical Drug Interactions

Contraindicated:

• Strong CYP3A inhibitors (itraconazole, ketoconazole, clarithromycin, ritonavir) 1, 2

Avoid or reduce dose with:

• Moderate CYP3A inhibitors (fluconazole, erythromycin, diltiazem, verapamil, grapefruit juice) 1

Monitor closely with:

• Diuretics (increased overcorrection risk) 2
• Potassium-sparing agents if baseline K+ >5 mEq/L 2

Common Pitfalls to Avoid

1. Fluid restriction during first 24 hours - counterintuitively increases overcorrection risk 2
2. Starting at full dose in severe hyponatremia - recent evidence suggests 7.5 mg starting dose may be safer for baseline sodium <125 mEq/L 3
3. Inadequate monitoring frequency - sodium can rise rapidly; 6-8 hour checks are essential initially 2
4. Missing liver monitoring in ADPKD - hepatotoxicity peaks in first 18 months 1
5. Continuing during volume depletion - hold during illness, vomiting, or limited water access 1

Additional Monitoring Parameters

• Volume status: Watch for dehydration/hypovolemia signs (especially with concurrent diuretics) 2
• Urine output: Expect marked aquaresis; ensure adequate fluid intake to match losses 1
• Potassium: Monitor if baseline >5 mEq/L or on ACE-I/ARB/K-sparing diuretics 2
• Neurologic exam: Assess for confusion, gait changes, or other CNS symptoms 2